盘状结构域受体2及其在肿瘤中的表达和作用

摘要/Abstract

摘要： 盘状结构域受体2（DDR2）是一种受体酪氨酸激酶（RTK），可以被多种胶原（Ⅰ~Ⅲ、Ⅹ型）激活。近年来研究发现DDR2在人类多种肿瘤中呈差异性表达，提示其可能参与肿瘤的发生和发展过程，DDR2将来可能作为肿瘤基因治疗的一个潜在靶点。

关键词: 胶原, 肿瘤, 盘状结构域受体2

Abstract: Discoidin domain receptor 2 (DDR2) is a receptor tyrosine kinase (RTK) that can be activated by fibrillar collagens （ⅠⅢ , Ⅹ）.Recently researchers show that the DDR2 is expressed differently in many cancers，which suggests DDR2 is probably correlated with tumorigenesis and cancer development，and it may become a promising cancer therapeutic target.

Key words: Collagen, Neoplasms, Discoidin domain receptor 2

王雷, 刘东明. 盘状结构域受体2及其在肿瘤中的表达和作用[J]. 国际肿瘤学杂志, 2016, 43(2): 126-.

WANG Lei, LIU Dong-Ming. Discoidin domain receptor 2 and its expression and role in tumor[J]. Journal of International Oncology, 2016, 43(2): 126-.

参考文献

［1］ Valiathan RR, Marco M, Leitinger B, et al. Discoidin domain receptor tyrosine kinases: new players in cancer progression［J］. Cancer Metastasis Rev， 2012, 31(12):295321. DOI:10.1007/s105550129346z. ［2］ Ikeda K, Wang LH, Torres R, et al. Discoidin domain receptor 2 interacts with Src and Shc following its activation by type Ⅰ collagen［J］. J Biol Chem， 2002, 277(21):1920619212. DOI:10.1074/jbc.M201078200. ［3］ Mishra VK, Johnsen SA.Targeted therapy of epigenomic regulatory mechanisms controlling the epithelial to mesenchymal transition during tumor progression［J］.Cell Tissue Res, 2014, 356(3):617630. DOI:10.1007/s004410141912y. ［4］ Liu XQ, Fan DM. The epithelialmesenchymal transition and cancer stem cells: functional and mechanistic links［J］.Curr Pharm Des, 2015, 21(10):12791291. ［5］朱蕾, 隋华, 邓皖利. 信号通路调控上皮间质转化参与肿瘤侵袭转移的分子机制［J］. 国际肿瘤学杂志， 2014, 41(3):172177. DOI: DOI:10.3760/cma.j.issn.1673422X.2014.03.004. ［6］ Walsh LA, Nawshad A, Medici D. Discoidin domain receptor 2 is a critical regulator of epithelialmesenchymal transition［J］. Matrix Biol， 2011, 30(4):243247. DOI:10.1016/j.matbio.2011.03.007. ［7］任婷婷. DDR2在肿瘤低氧适应中的作用研究［D］.西安: 第四军医大学， 2010. ［8］ Maeyama M, Koga H, Selvendiran K, et al. Switching in discoid domain receptor expressions in SLUGinduced epithelialmesenchymal transition［J］. Cancer， 2008, 113(10):28232831. DOI:10.1002/cncr.23900. ［9］ Davies H, Hunter C, Smith R, et al. Somatic mutations of the protein kinase gene family in human lung cancer［J］. Cancer Res， 2005, 65(17):75917595. DOI:10.1158/00085472.CAN051855. ［10］ Ford CE, Lau SK, Zhu CQ, et al. Expression and mutation analysis of the discoidin domain receptors 1 and 2 in nonsmall cell lung carcinoma［J］. Br J Cancer, 2007, 96(5):808814. DOI:10.1038/sj.bjc.6603614. ［11］ Sasaki H, Shitara M, Yokota K, et al. DDR2 polymorphisms and mRNA expression in lung cancers of Japanese patients［J］. Oncol Lett， 2012, 4(1):3337. DOI:10.3892/ol.2012.684. ［12］ Hammerman PS, Sos ML, Ramos AH, et al. Mutations in the DDR2 kinase gene identify a Novel therapeutic target in squamous cell lung cancer［J］. Cancer discov， 2011, 1(1):7889. DOI:10.1158/21598274.CD110005. ［13］ Pitini V, Arrigo C, Di Mirto C, et al. Response to dasatinib in a patient with SQCC of the lung harboring a discoidreceptor2 and synchronous chronic myelogenous leukemia［J］. Lung Cancer， 2013, 82(1):171172. DOI:10.1016/j.lungcan.2013.07.004. ［14］ An SJ, Chen ZH, Su J, et al. Identification of enriched driver gene alterations in subgroups of nonsmall cell lung cancer patients based on histology and smoking status［J］. PLoS One， 2012, 7(6):e40109. DOI:10.1371/journal.pone.0040109. ［15］ Chua HH, Yeh TH, Wang YP, et al. Upregulation of discoidin domain receptor 2 in nasopharyngeal carcinoma［J］. Head Neck, 2008, 30(4):427436. DOI:10.1002/hed.20724. ［16］ Xu J, Lu W, Zhang S, et al. Overexpression of DDR2 contributes to cell invasion and migration in head and neck squamous cell carcinoma［J］. Cancer Biol Ther， 2014, 15(5):612622. DOI:10.4161/cbt.28181. ［17］ Park HS, Kim KR, Lee HJ, et al. Overexpression of discoidin domain receptor 1 increases the migration and invasion of hepatocellular carcinoma cells in association with matrix metalloproteinase［J］. Oncol Rep， 2007, 18(6):14351441. ［18］ Lee NO, Park JW, Lee JA, et al. Dual action of a selective cyclooxygenase2 inhibitor on vascular endothelial growth factor expression in human hepatocellular carcinoma cells: novel involvement of discoidin domain receptor 2［J］. J Cancer Res Clin Oncol, 2012, 138(1):7384. DOI:10.1007/s0043201110750. ［19］ Park JW, Lee YS, Kim JS, et al. Downregulation of discoidin domain receptor 2 decreases tumor growth of hepatocellular carcinoma［J］. J Cancer Res Clin Oncol, 2015, 141(11):19731983. DOI:10.1007/s0043201519675. ［20］武曼群, 杨少奇, 赵进, 等. 盘状结构域受体在人肝癌、肝硬化与正常肝组织中的表达及其意义［J］.宁夏医学杂志, 2014, 36(9):824826. ［21］ Ren T, Zhang J, Zhang J, et al. Increased expression of discoidin domain receptor 2 (DDR2): a novel independent prognostic marker of worse outcome in breast cancer patients［J］. Med Oncol, 2013, 30(1):397. DOI:10.1007/s1203201203973. ［22］ Ren T, Zhang W, Liu X, et al. Discoidin domain receptor 2 (DDR2) promotes breast cancer cell metastasis and the mechanism implicates epithelialmesenchymal transition programme under hypoxia［J］. J Pathol, 2014, 234(4):526537. DOI:10.1002/path.4415. ［23］ Zhang K, Corsa CA, Ponik SM, et al. The collagen receptor discoidin domain receptor 2 stabilizes SNAIL1 to facilitate breast cancer metastasis［J］. Nat Cell Biol, 2013, 15(6):677687. DOI:10.1038/ncb2743. ［24］ Toy KA, Valiathan RR, Núez F, et al. Tyrosine kinase discoidin domain receptors DDR1 and DDR2 are coordinately deregulated in triplenegative breast cancer［J］. Breast Cancer Res Treat， 2015, 150(1):918. DOI:10.1007/s1054901532857. ［25］ Yan Z, Jin S, Wei Z, et al. Discoidin domain receptor 2 facilitates prostate cancer bone metastasis via regulating parathyroid hormonerelated protein［J］. Biochim Biophys Acta， 2014, 1842(9):13501363. DOI:10.1016/j.bbadis.2014.04.018.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青. 血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志. 宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.